Basel, Switzerland, July 1, 2015 – Alcon, the global leader in eye care and a division of Novartis, has received European CE Mark for its AcrySof® IQ Aspheric IOL with the UltraSert™ Pre-loaded ...
Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for cataract patients.
MarketBeat on MSN
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook
Key Points Interested in RxSight, Inc.? Here are five stocks we like better. RxSight's preliminary Q2 sales fell 20% year over year to about $27 million excluding collaboration revenue, with Light ...
“Alcon is proud to be the title sponsor of SECO 2020 and welcomes the opportunity to connect with Eye Care Professionals (ECPs) while providing hands-on access to our latest, innovative eye care ...
The FINANCIAL — Alcon, one of the global leaders in eye care and a division of Novartis, has received European CE Mark for its AcrySof IQ Aspheric IOL with the UltraSertTM Pre-loaded Delivery System ...
The FINANCIAL — Alcon, one of the global leaders in eye care and a division of Novartis, has received US Food and Drug Administration (FDA) approval for its AcrySof IQ Aspheric IOL with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results